Get access

Hepatic resection for colorectal metastases

Authors

  • Timothy L. Frankel MD,

    Corresponding author
    1. Section of Hepatopancreatobiliary Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    • Correspondence to: Timothy L. Frankel, MD, Department of Surgery, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109. Fax: 734-232-6188.

      E-mail: timofran@med.umich.edu

    Search for more papers by this author
  • Michael I. D'Angelica MD

    1. Section of Hepatopancreatobiliary Surgery, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
    Search for more papers by this author

  • Authors report no disclosures or funding.

Abstract

The liver represents a common site for metastasis in colorectal cancer. Improvements in patient selection and surgical techniques has resulted in improved outcomes following hepatic metastasectomy with large series reporting 5- and 10-year overall survival rates of 40% and 20%, respectively. In recent years, criteria for resectability has expanded with the use of forced liver hypertrophy and staged resection. The role of perioperative chemotherapy remains controversial with a slight increase in survival and operative morbidity. J. Surg. Oncol. 2014 109:2–7. © 2013 Wiley Periodicals, Inc.

Ancillary